Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: A preliminary study

被引:4
|
作者
Ojha, Rohit P. [1 ]
Hanzis, Christina A. [2 ]
Hunter, Zachary R. [2 ]
Greenland, Sander [3 ,4 ]
Offutt-Powell, Tabatha N. [5 ]
Manning, Robert J. [2 ]
Lewicki, Megan [2 ]
Brodsky, Philip S. [2 ]
Ioakimidis, Leukothea [2 ]
Tripsas, Christina K. [2 ]
Patterson, Christopher J. [2 ]
Sheehy, Patricia [2 ]
Singh, Karan P. [6 ]
Treon, Steven P. [2 ,7 ]
机构
[1] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA
[4] Univ Calif Los Angeles, Coll Letters & Sci, Dept Stat, Los Angeles, CA USA
[5] Univ N Texas, Hlth Sci Ctr, Dept Epidemiol, Sch Publ Hlth, Ft Worth, TX USA
[6] Univ N Texas, Hlth Sci Ctr, Dept Biostat, Sch Publ Hlth, Ft Worth, TX USA
[7] Harvard Univ, Sch Med, Boston, MA USA
关键词
Waldenstrom Macroglobulinemia; Epidemiology; Family history; Risk factor; Breast cancer; Colorectal cancer; Lung cancer; Ovarian cancer; Prostate cancer; MUTATIONS;
D O I
10.1016/j.canep.2011.10.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Little is known about the epidemiology and etiology of Waldenstrom macroglobulinemia (WM). Despite several studies of the relation between family history and B-cell disorders and WM, family history of non-hematologic cancers has not been systematically investigated. We thus examined associations of family history of breast, colorectal, lung, ovarian, and prostate cancers with WM. Methods: All probands aged 20-79 years with bone marrow biopsy-confirmed diagnosis of WM between May 1, 1999 and January 1, 2010 at the Bing Center for Waldenstrom Macroglobulinemia were eligible for inclusion in our analysis. We reviewed medical records for eligible probands to determine family history of cancer (defined as a cancer diagnosis for >1 first-degree relative(s) of the proband). Using expected values constructed from the United States National Health Interview Survey, we estimated age- and race-standardized rate ratios (RRs) for family history of breast, colorectal, lung, ovarian, and prostate cancers by WM subtype. Results: Family history of prostate cancer had the largest overall rate ratio (RR = 1.4, 95% confidence limits [CL]: 1.1, 1.7), and among sporadic cases, family history of prostate and breast cancer had the largest rate ratios (prostate: RR = 1.3, 95% CL: 1.1, 1.7; breast: RR = 1.3, 95% CL: 1.2, 1.6). Conclusion: Our study suggests that it may be worthwhile to pursue these associations in a case-control study with uniform selection and data collection for cases and controls, and at least some record-based information on family history. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:294 / 297
页数:4
相关论文
共 50 条
  • [21] Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies
    Ahmed Hamed Salem
    Vincent L. Giranda
    Nael M. Mostafa
    Clinical Pharmacokinetics, 2014, 53 : 479 - 488
  • [22] WALDENSTROM MACROGLOBULINEMIA AND PERIPHERAL NEUROPATHY - A CLINICAL AND IMMUNOLOGICAL STUDY OF 25 PATIENTS
    DELLAGI, K
    DUPOUEY, P
    BROUET, JC
    BILLECOCQ, A
    GOMEZ, D
    CLAUVEL, JP
    SELIGMANN, M
    BLOOD, 1983, 62 (02) : 280 - 285
  • [23] The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review
    Jennifer R. Landes
    Stephen A. Moore
    Brooke R. Bartley
    Hung Q. Doan
    Peter L. Rady
    Stephen K. Tyring
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2139 - 2155
  • [24] Non-Hematologic Therapy Toxicities Correlated with Survival, Drug Discontinuation and Response in Multiple Myeloma Patients: A Retrospective Study
    Huang, Weimin
    Wei, Yongqiang
    Zheng, Jingxia
    Wei, Xiaolei
    Feng, Ru
    BLOOD, 2019, 134
  • [25] Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
    Smith, David C.
    Kalebic, Thea
    Infante, Jeffrey R.
    Siu, Lillian L.
    Sullivan, Daniel
    Vlahovic, Gordana
    Kauh, John S.
    Gao, Feng
    Berger, Allison J.
    Tirrell, Stephen
    Gupta, Neeraj
    Di Bacco, Alessandra
    Berg, Deborah
    Liu, Guohui
    Lin, Jianchang
    Hui, Ai-Min
    Thompson, John A.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) : 652 - 663
  • [26] Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies
    Salem, Ahmed Hamed
    Giranda, Vincent L.
    Mostafa, Nael M.
    CLINICAL PHARMACOKINETICS, 2014, 53 (05) : 479 - 488
  • [27] Association of non-hematologic acute toxicities of chemoradiotherapy in esophageal cancer patients with DNA damage
    Imano, Nobuki
    Nagata, Yasushi
    Tashiro, Satoshi
    CANCER SCIENCE, 2021, 112 : 597 - 597
  • [28] Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
    David C. Smith
    Thea Kalebic
    Jeffrey R. Infante
    Lillian L. Siu
    Daniel Sullivan
    Gordana Vlahovic
    John S. Kauh
    Feng Gao
    Allison J. Berger
    Stephen Tirrell
    Neeraj Gupta
    Alessandra Di Bacco
    Deborah Berg
    Guohui Liu
    Jianchang Lin
    Ai-Min Hui
    John A. Thompson
    Investigational New Drugs, 2015, 33 : 652 - 663
  • [29] Prevalence of autoimmune hematologic and non-hematologic conditions in large granular lymphocytic leukemia: exploratory analysis of a series of consecutive patients
    Bockorny, Bruno
    Codreanu, Ion
    Dasanu, Constantin A.
    LEUKEMIA & LYMPHOMA, 2014, 55 (06) : 1399 - 1401
  • [30] Cognitive Impairment Among Older Patients With Hematologic Cancers
    Tanimoto, Tetsuya
    Morita, Tomohiro
    Tsuda, Kenji
    JAMA ONCOLOGY, 2018, 4 (12) : 1783 - 1784